ストックスクリーナーアプリを入手
89.31
1.42%
1.25
アフターアワーズ：
90.00
0.69
+0.77%
前日終値:
$88.06
開ける：
$87.65
24時間の取引高:
2.03M
Relative Volume:
1.14
時価総額：
$17.44B
収益：
$4.58B
当期純損益:
$870.87M
株価収益率:
20.30
EPS:
4.3988
ネットキャッシュフロー:
$945.58M
1週間 パフォーマンス:
+2.29%
1か月 パフォーマンス:
+5.64%
6か月 パフォーマンス:
+53.98%
1年 パフォーマンス:
+37.04%
1日の値動き範囲:
$87.50
$89.56
1週間の範囲:
$84.38
$89.56
52週間の値動き範囲:
$53.56
$92.86
Incyte Corp Stock (INCY) Company Profile
INCY を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
89.31 | 17.05B | 4.58B | 870.87M | 945.58M | 4.3988 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.63 | 109.29B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.00 | 62.13B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
575.69 | 61.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.18 | 51.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
310.03 | 34.68B | 4.56B | -176.77M | 225.30M | -1.7177 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-08 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2025-08-06 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2025-08-01 | 開始されました | Barclays | Overweight |
| 2025-06-16 | アップグレード | Stifel | Hold → Buy |
| 2025-03-18 | ダウングレード | Guggenheim | Buy → Neutral |
| 2025-03-18 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2024-12-17 | 開始されました | UBS | Neutral |
| 2024-10-29 | アップグレード | BofA Securities | Neutral → Buy |
| 2024-10-01 | 開始されました | Wolfe Research | Outperform |
| 2024-09-18 | ダウングレード | Truist | Buy → Hold |
| 2024-07-02 | ダウングレード | BMO Capital Markets | Market Perform → Underperform |
| 2024-05-23 | 開始されました | Deutsche Bank | Hold |
| 2024-04-23 | 開始されました | Cantor Fitzgerald | Neutral |
| 2024-02-23 | 開始されました | Jefferies | Buy |
| 2024-02-14 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-13 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2023-12-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2023-11-21 | ダウングレード | Goldman | Buy → Neutral |
| 2023-07-25 | 開始されました | Citigroup | Buy |
| 2023-05-04 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-04-10 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-03-24 | アップグレード | SVB Securities | Underperform → Market Perform |
| 2023-01-31 | 開始されました | Piper Sandler | Overweight |
| 2022-08-03 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-08-03 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-07-28 | 開始されました | Wells Fargo | Equal Weight |
| 2022-02-09 | ダウングレード | SVB Leerink | Mkt Perform → Underperform |
| 2022-01-18 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-19 | 開始されました | BMO Capital Markets | Market Perform |
| 2021-07-20 | アップグレード | The Benchmark Company | Hold → Buy |
| 2021-02-10 | ダウングレード | SVB Leerink | Mkt Perform → Underperform |
| 2021-01-07 | 開始されました | Truist | Buy |
| 2021-01-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-06-16 | 開始されました | The Benchmark Company | Hold |
| 2020-05-06 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-04-29 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-01 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-24 | 再開されました | William Blair | Outperform |
| 2020-03-13 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2020-02-04 | 再開されました | BofA/Merrill | Neutral |
| 2020-01-03 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2020-01-03 | ダウングレード | Mizuho | Buy → Neutral |
| 2020-01-02 | ダウングレード | Guggenheim | Buy → Neutral |
| 2019-10-03 | 開始されました | Mizuho | Buy |
| 2019-09-12 | 開始されました | BMO Capital Markets | Market Perform |
| 2019-09-05 | アップグレード | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-09-05 | 再開されました | Morgan Stanley | Equal-Weight |
| 2019-09-05 | アップグレード | Oppenheimer | Perform → Outperform |
| 2019-05-21 | 開始されました | Credit Suisse | Neutral |
| 2019-05-03 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2019-04-11 | 開始されました | Stifel | Hold |
| 2019-04-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-01-24 | アップグレード | William Blair | Mkt Perform → Outperform |
すべてを表示
Incyte Corp (INCY) 最新ニュース
This biotech made it through a 'time correction.' The charts say it could be time to buy - CNBC
Can a trend reversal in Incyte Corporation lead to recovery2025 Earnings Impact & Weekly Top Gainers Trade List - newser.com
Can Incyte Corporation (ICY) stock attract analyst upgradesWeekly Investment Recap & Weekly Breakout Stock Alerts - newser.com
What’s next for Incyte Corporation stock price2025 Trading Volume Trends & AI Driven Stock Reports - newser.com
What risks investors should watch in Incyte Corporation stockWeekly Trade Report & Weekly High Potential Stock Alerts - newser.com
Will Incyte Corporation (ICY) stock see insider accumulationPortfolio Gains Summary & Real-Time Market Trend Scan - newser.com
Does Incyte Corporation show high probability of reboundPortfolio Profit Report & Fast Moving Stock Watchlists - newser.com
Incyte: Strong Growth, Margin Expansion, And Low Valuation - Seeking Alpha
Multi asset correlation models including Incyte CorporationWeekly Profit Report & Growth Focused Entry Reports - newser.com
Will Incyte Corporation (ICY) stock enhance shareholder valueTrade Signal Summary & Intraday High Probability Alerts - newser.com
Incyte Claims Sun Pharma's Alopecia Drug Launch Violates IP - Law360
Is Incyte Corporation (ICY) stock among top earnings playsWeekly Volume Report & High Conviction Buy Zone Picks - newser.com
Incyte Corp. Stock Underperforms Monday When Compared To Competitors - 富途牛牛
Incyte (INCY) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
Incyte's Quarterly Earnings Preview: What You Need to Know - Yahoo Finance
Real time alert setup for Incyte Corporation performance2025 Winners & Losers & Free Community Supported Trade Ideas - newser.com
Is Incyte Corporation (ICY) stock undervalued by metricsWeekly Trend Summary & Safe Capital Investment Plans - newser.com
Is Incyte Corporation (ICY) stock dividend growth reliable2025 Breakouts & Breakdowns & Growth Oriented Trading Recommendations - newser.com
Assessing Incyte’s Share Price After Recent FDA Approval and Strong 2024 Gains - Yahoo Finance
Are You Looking for a Top Momentum Pick? Why Incyte (INCY) is a Great Choice - sharewise.com
Incyte to Report Third Quarter 2025 Financial Results on October 28 - MyChesCo
Lobbying Update: $80,000 of INCYTE CORPORATION lobbying was just disclosed - Quiver Quantitative
Incyte (INCY) Reports Encouraging Clinical Trial Data at ESMO Co - GuruFocus
Incyte at ESMO Congress 2025: Strategic Focus on Tumor Programs - Investing.com
Incyte’s cancer drug candidates show promising results in trials - Investing.com
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma - The AI Journal
What technical charts say about Incyte Corporation stockLong Setup & Long-Term Safe Investment Plans - nchmf.gov.vn
Is Incyte Corporation stock a defensive play in 20252025 Big Picture & Reliable Entry Point Trade Alerts - nchmf.gov.vn
Bollinger, Credo, Ambarella, Cipher, Incyte: Insider Moves Unveiled! - TipRanks
Is Incyte Corporation (ICY) stock a defensive play amid uncertaintyWeekly Trend Summary & Real-Time Volume Trigger Notifications - nchmf.gov.vn
How Incyte Corporation stock performs in rising dollar environmentMarket Performance Summary & Proven Capital Preservation Tips - newser.com
InvestingPro’s Fair Value model captures 63% gain in Incyte shares By Investing.com - Investing.com
How Incyte Corporation stock responds to policy changesTrade Volume Report & Consistent Return Strategy Ideas - newser.com
Incyte (INCY) Stock Is Up, What You Need To Know - Barchart.com
Incyte Corporation stock hits 52-week high at 88.78 USD - Investing.com
Incyte (INCY) Price Target Lifted on CALR Antibody Program Optimism - MSN
Can Incyte Corporation rally from current levels2025 Top Gainers & Reliable Price Breakout Alerts - newser.com
Sjogren’s Syndrome Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates | Gilead Sciences, Incyte Corp, Novartis, GlaxoSmithKline, Janssen Research & Development, LLC - Barchart.com
Sjogren's Syndrome Market Insights Highlight Expanding - openPR.com
Incyte Canada Announces Health Canada approval of Opzelura® (Ruxolitinib) Cream for the Treatment of Atopic Dermatitis in Children Ages 2-11 - Yahoo
Using Python tools to backtest Incyte Corporation strategiesMarket Movers & Fast Entry Momentum Trade Alerts - newser.com
Incyte's (INCY) EVP and General Counsel Sold 4,100 Shares for $352,000 - The Globe and Mail
Incyte stock price target raised to $76 from $68 at UBS on valuation By Investing.com - Investing.com South Africa
Incyte stock price target raised to $76 from $68 at UBS on valuation - Investing.com India
Incyte Corp (INCY) 財務データ
収益
当期純利益
現金流量
EPS
Incyte Corp (INCY) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Denton Sheila A. | EVP & General Counsel |
Oct 15 '25 |
Sale |
85.13 |
277 |
23,581 |
26,569 |
0.03%
0.17%
大文字化:
|
ボリューム (24 時間):